Asta Juzeniene1, Vilde Yuli Stenberg1,2,3, Øyvind Sverre Bruland3,4, Roy Hartvig Larsen2. 1. Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway. 2. Nucligen, Ullernchausséen 64, 0379 Oslo, Norway. 3. Institute for Clinical Medicine, University of Oslo, Box 1171 Blindern, 0318 Oslo, Norway. 4. Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway.
Abstract
Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months' survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β- therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.
Bone, lymph node, and visceral metastases are frequeical">nt iical">n castn class="Species">rate-resistant prostate cancerpatients. Since such patients have only a few months' survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β- therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.
Authors: Lena M Unterrainer; Leonie Beyer; Mathias J Zacherl; Franz J Gildehaus; Andrei Todica; Sophie C Kunte; Adrien Holzgreve; Gabriel T Sheikh; Annika Herlemann; Jozefina Casuscelli; Matthias Brendel; Nathalie L Albert; Vera Wenter; Nina-Sophie Schmidt-Hegemann; Wolfgang G Kunz; Clemens C Cyran; Jens Ricke; Christian G Stief; Peter Bartenstein; Harun Ilhan; Marcus Unterrainer Journal: Biomedicines Date: 2022-04-20
Authors: Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren Journal: Pharmaceutics Date: 2021-04-21 Impact factor: 6.321
Authors: Sashi Debnath; Ning Zhou; Mark McLaughlin; Samuel Rice; Anil K Pillai; Guiyang Hao; Xiankai Sun Journal: Int J Mol Sci Date: 2022-01-21 Impact factor: 5.923
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236